Robert Andrew Douglas Sells 1,147 Shares of ResMed Inc. (NYSE:RMD) Stock

ResMed Inc. (NYSE:RMD) COO Robert Andrew Douglas sold 1,147 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $175.49, for a total value of $201,287.03. Following the sale, the chief operating officer now directly owns 24,620 shares in the company, valued at $4,320,563.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Robert Andrew Douglas also recently made the following trade(s):

  • On Wednesday, July 15th, Robert Andrew Douglas sold 1,026 shares of ResMed stock. The shares were sold at an average price of $196.98, for a total value of $202,101.48.

NYSE:RMD traded down $1.49 during mid-day trading on Wednesday, hitting $174.06. 544,208 shares of the company’s stock traded hands, compared to its average volume of 699,658. The firm has a 50 day moving average of $183.19 and a two-hundred day moving average of $170.00. ResMed Inc. has a 12 month low of $108.85 and a 12 month high of $208.99. The firm has a market capitalization of $25.22 billion, a price-to-earnings ratio of 40.76, a price-to-earnings-growth ratio of 2.62 and a beta of 0.36. The company has a current ratio of 2.53, a quick ratio of 1.84 and a debt-to-equity ratio of 0.47.

ResMed (NYSE:RMD) last announced its earnings results on Wednesday, August 5th. The medical equipment provider reported $1.33 earnings per share for the quarter, beating the consensus estimate of $0.97 by $0.36. ResMed had a return on equity of 30.34% and a net margin of 21.02%. The firm had revenue of $770.30 million during the quarter, compared to the consensus estimate of $755.01 million. During the same quarter in the prior year, the company earned $0.95 EPS. The firm’s revenue for the quarter was up 9.3% compared to the same quarter last year. As a group, equities research analysts expect that ResMed Inc. will post 4.73 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 24th. Investors of record on Thursday, August 20th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Wednesday, August 19th. This represents a $1.56 annualized dividend and a yield of 0.90%. ResMed’s payout ratio is 32.77%.

Several hedge funds have recently made changes to their positions in the business. BlackRock Inc. lifted its position in shares of ResMed by 7.0% in the 2nd quarter. BlackRock Inc. now owns 13,203,838 shares of the medical equipment provider’s stock worth $2,535,139,000 after acquiring an additional 859,377 shares during the period. WCM Investment Management LLC lifted its position in shares of ResMed by 3.7% in the 2nd quarter. WCM Investment Management LLC now owns 8,468,653 shares of the medical equipment provider’s stock worth $1,625,981,000 after acquiring an additional 299,913 shares during the period. State Street Corp lifted its position in shares of ResMed by 3.4% in the 1st quarter. State Street Corp now owns 6,657,104 shares of the medical equipment provider’s stock worth $980,525,000 after acquiring an additional 218,417 shares during the period. Geode Capital Management LLC lifted its position in shares of ResMed by 1.3% in the 1st quarter. Geode Capital Management LLC now owns 2,459,327 shares of the medical equipment provider’s stock worth $361,642,000 after acquiring an additional 30,612 shares during the period. Finally, Invesco Ltd. lifted its position in shares of ResMed by 21.5% in the 1st quarter. Invesco Ltd. now owns 2,446,398 shares of the medical equipment provider’s stock worth $360,330,000 after acquiring an additional 432,805 shares during the period. Institutional investors own 69.38% of the company’s stock.

RMD has been the topic of several research reports. Oppenheimer upped their target price on ResMed from $200.00 to $210.00 in a research report on Thursday, August 6th. Goldman Sachs Group downgraded ResMed from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. Needham & Company LLC reiterated a “hold” rating on shares of ResMed in a research note on Thursday, August 6th. Zacks Investment Research downgraded ResMed from a “buy” rating to a “hold” rating and set a $184.00 price target for the company. in a research note on Tuesday, August 11th. Finally, Morgan Stanley downgraded ResMed from an “overweight” rating to an “equal weight” rating in a research note on Thursday, August 6th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and two have issued a buy rating to the company’s stock. ResMed presently has an average rating of “Hold” and a consensus target price of $186.00.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Featured Article: Compound Interest and Why It Matters When Investing

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.